---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000140"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:11:03.777658+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%

## Summary
- Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.
- Combined with prior undertakings from August 8, shareholders holding ~53% of Exscientia now committed to support the deal.
- The transaction is structured as a scheme of arrangement under UK Companies Act, with Recursion acquiring all Exscientia share capital.
- Irrevocable undertaking prohibits Evotec from accepting competing offers or taking actions that impede the deal.

## SEC filing metadata
- accession: 0001601830-24-000140
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000140/0001601830-24-000140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000140/rxrx-20240828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000140
- JSON: https://secwatch.observer/filing/0001601830-24-000140.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.